Bio News
U.S.-based Lisata Therapeutics will merge with cardiovascular-focused company Marea Therapeutics in a stock-for-stock transaction. Following the merger, existing Lisata shareholders will hold approximately 2.4% of the combined company. Lisata will focus on developing Marea’s two clinical phase 2 candidates.
Biobook Team
biobookmedia@biobook.co.krIpscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Ipscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
